Skip to main content
Biocartis Group NV logo

Biocartis Group NV — Investor Relations & Filings

Ticker · BCART ISIN · BE0974281132 LEI · 549300J4HOJL5KG8HY54 BR Manufacturing
Open in API
Filings indexed 636 across all filing types
Latest filing 2019-05-09 Capital/Financing Update
Country BE Belgium
Listing BR BCART

About Biocartis Group NV

https://www.biocartis.com/en

Biocartis Group NV is a molecular diagnostics company that develops and commercializes its proprietary Idylla™ platform. This fully automated, sample-to-result system is designed to provide fast, easy, and actionable molecular diagnostic results, making advanced testing accessible to laboratories of any size. The company's primary focus is in the field of oncology, offering a menu of tests that support the diagnosis and treatment of various cancers, including lung, colorectal, melanoma, and breast cancer. Biocartis aims to enable personalized medicine for patients by providing universal access to molecular testing. The company also collaborates with pharmaceutical partners in the development of companion diagnostics.

Recent filings

Filing Released Lang Actions
Special board report pursuant to Art. 583 and 596 BCC.pdf
Capital/Financing Update Classification · 95% confidence The document is explicitly titled a "SPECIAL REPORT OF THE BOARD OF DIRECTORS IN ACCORDANCE WITH ARTICLES 583 AND 596 OF THE BELGIAN COMPANIES CODE". This report details a proposal by the board of directors to issue senior unsecured convertible bonds (a financing activity) and justifies the dis-application of the statutory preferential subscription right. This content strongly aligns with documents related to capital structure changes, financing activities, and specific regulatory reporting required for such corporate actions under Belgian law. While it involves capital structure changes (CAP), the document's primary function is a formal, legally mandated report explaining the rationale for a major financing/capital decision, which often falls under specific corporate governance or financing disclosure rules. Given the options, the issuance of bonds and the associated capital structure change points towards 'Capital/Financing Update' (CAP). However, the document is a detailed, formal report mandated by specific articles of the Belgian Companies Code concerning the issuance of securities and the waiver of shareholder rights, which is a specific type of corporate action disclosure. Since the core subject is the issuance of convertible bonds (a financing activity) and the justification for bypassing pre-emptive rights, 'CAP' (Capital/Financing Update) is the most fitting category, as it covers fundraising and capital structure changes. It is not a general 10-K, an ER, or a simple RPA.
2019-05-09 English
Bijzonder verslag raad van bestuur overeenk. art. 583 en 596 W. Venn.pdf
Management Reports Classification · 99% confidence The document is titled "BIJZONDER VERSLAG VAN DE RAAD VAN BESTUUR OVEREENKOMSTIG DE ARTIKELEN 583 EN 596 VAN HET WETBOEK VAN VENNOOTSCHAPPEN" (Special Report of the Board of Directors pursuant to Articles 583 and 596 of the Companies Code). It details a proposal by the Board of Directors to issue convertible bonds (Obligaties) up to EUR 150 million and requests the lifting of the statutory pre-emption rights of existing shareholders for this private placement via an accelerated book-building procedure. This type of document, which explains a significant corporate action involving capital structure changes (issuance of debt convertible into equity) and requires board justification and shareholder approval (implied by the reference to lifting pre-emption rights), strongly aligns with a financing or capital structure update. Since the core subject is the issuance of debt instruments (convertible bonds) for fundraising and capital optimization, the most appropriate category is 'Capital/Financing Update' (CAP). It is not a standard Annual Report (10-K), an Earnings Release (ER), or a simple Dividend Notice (DIV). It is a detailed report explaining a capital transaction.
2019-05-09 Dutch
BIOCARTIS ANNOUNCES FINAL TERMS OF ITS EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024
Capital/Financing Update Classification · 99% confidence The document is explicitly titled a "PRESS RELEASE REGULATED INFORMATION – INSIDE INFORMATION" and announces the "FINAL TERMS OF ITS EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024". This clearly indicates a corporate action related to financing, specifically the pricing and terms of a bond offering. This falls directly under the definition of Capital/Financing Update (CAP). It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it concerns a specific capital market transaction.
2019-05-02 English
BIOCARTIS KONDIGT DE DEFINITIEVE VOORWAARDEN AAN VAN ZIJN NIET-GESUBORDINEERDE, NIET-GEWAARBORGDE CONVERTEERBARE OBLIGATIES VAN EUR 150 MILJOEN DIE VERVALLEN OP 9 MEI 2024
Capital/Financing Update Classification · 98% confidence The document is titled "PERSBERICHT GEREGLEMENTEERDE INFORMATIE" (Regulated Information Press Release) and announces the final terms for a EUR 150 million offering of convertible bonds ("CONVERTEERBARE OBLIGATIES"). This clearly relates to a financing activity, specifically the issuance of debt securities convertible into equity. This aligns directly with the definition of 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it concerns a specific capital market transaction.
2019-05-02 Dutch
BIOCARTIS ANNOUNCES SUCCESSFUL PLACEMENT OF EUR 150 MILLION SENIOR UNSECURED CONVERTIBLE BONDS DUE 9 MAY 2024
Capital/Financing Update Classification · 98% confidence The document is a press release announcing the successful placement of EUR 150 million in senior unsecured convertible bonds. This action directly relates to the company raising capital and changing its financing structure. Based on the provided definitions, the category 'Capital/Financing Update' (Code: CAP) is the most appropriate classification, as it covers updates on company fundraising and financing activities. It is not an Earnings Release (ER), Interim Report (IR), or a general Regulatory Filing (RNS), as it describes a specific financing event.
2019-05-02 English
BIOCARTIS KONDIGT DE SUCCESVOLLE PLAATSING AAN VAN NIET-GESUBORDINEERDE, NIET-GEWAARBORGDE CONVERTEERBARE OBLIGATIES VAN EUR 150 MILJOEN DIE VERVALLEN OP 9 MEI 2024
Capital/Financing Update Classification · 99% confidence The document is a press release (Persbericht) dated May 2, 2019, announcing the successful placement of EUR 150 million in convertible bonds. The content focuses entirely on a financing activity: the issuance of debt securities (obligations) and the intended use of proceeds to fund growth. This directly aligns with the definition of 'Capital/Financing Update' (CAP). It is not an Annual Report (10-K), an Earnings Release (ER), or a general Regulatory Filing (RNS), as it details a specific capital structure event.
2019-05-02 Dutch

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.